Analysts expect Applied DNA Sciences, Inc. (NASDAQ:APDN) to announce earnings of ($0.18) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Applied DNA Sciences’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.24). Applied DNA Sciences posted earnings of ($0.79) per share during the same quarter last year, which would suggest a positive year over year growth rate of 77.2%. The business is expected to issue its next quarterly earnings results on Thursday, May 13th.
On average, analysts expect that Applied DNA Sciences will report full-year earnings of ($0.66) per share for the current year, with EPS estimates ranging from ($0.88) to ($0.44). For the next fiscal year, analysts expect that the firm will report earnings of $0.63 per share, with EPS estimates ranging from $0.40 to $0.85. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Applied DNA Sciences.
Applied DNA Sciences (NASDAQ:APDN) last issued its earnings results on Wednesday, February 10th. The technology company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.02). Applied DNA Sciences had a negative return on equity of 179.48% and a negative net margin of 672.79%. The business had revenue of $1.62 million for the quarter, compared to analyst estimates of $1.40 million.
A number of hedge funds have recently made changes to their positions in APDN. Squarepoint Ops LLC bought a new stake in Applied DNA Sciences in the third quarter valued at approximately $78,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Applied DNA Sciences during the 3rd quarter worth approximately $84,000. Golden Green Inc. bought a new position in shares of Applied DNA Sciences in the 4th quarter worth $70,000. Creative Planning lifted its holdings in shares of Applied DNA Sciences by 39.1% in the 4th quarter. Creative Planning now owns 81,145 shares of the technology company’s stock worth $414,000 after purchasing an additional 22,794 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Applied DNA Sciences in the 4th quarter valued at $186,000. Institutional investors and hedge funds own 7.04% of the company’s stock.
Shares of Applied DNA Sciences stock traded down $0.49 on Friday, hitting $7.74. The stock had a trading volume of 6,990 shares, compared to its average volume of 1,494,628. The stock has a 50 day moving average of $8.66 and a 200 day moving average of $8.12. Applied DNA Sciences has a twelve month low of $3.61 and a twelve month high of $16.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.01 and a current ratio of 2.13. The firm has a market capitalization of $57.84 million, a P/E ratio of -2.25 and a beta of 1.40.
Applied DNA Sciences Company Profile
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia.
Further Reading: How is a price target determined?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.